Table 1.

Characteristics of used HDACIs

Acronym in this study	Name	Marketed as	Approved for	Treatment corresponding to C max	Human tolerable plasmatic concentration (C max)	Selected doses in this study	Clinical trials in HIV field
MS‐275	Entinostat	n.a.	Ongoing clinical trials for the treatment of various cancers	For an usual dosage	0.14 ± 0.24–0.3 ± 0.22 μM (Wightman et al, 2013)	0.5 μM	n.a.
NaBut	Sodium butyrate	Buphenyl	Sickle cell anemia and beta‐thalassemia	For 27 and 36 g/day	1.225 and 1.605 mM (Phuphanich et al, 2005)	1.5 mM	n.a.
SAHA	Vorinostat, suberoylanilide hydroxamic acid	Zolinza	Cutaneous T‐cell lymphoma	For an usual dosage two times/day during 2–3 weeks	0.3–1.7 μM (Merck (2013) Zolinza (vorinostat) prescribing information)	1.25 μM	Archin et al (2014, 2012), Elliott et al (2014)
VPA	Valproic acid	Depakine	Chronic neurological and psychiatric disorders	For an usual dosage	0.25–0.5 mM (AbbVie (2014) Depakote prescribing information)	2.5 mM	Archin et al (2010, 2008), Lehrman et al (2005), Routy et al (2012a,b), Sagot‐Lerolle et al (2008), Siliciano et al (2007)
Beli	Belinostat, PXD101	Beleodaq	Relapsed or refractory peripheral T‐cell lymphoma	1,000 mg/m² for five consecutive days	> 1 μM (Steele et al, 2011)	1 μM	n.a.
Pano	Panobinostat, LBH‐589	Faridak	Myeloma therapy	For one dose with an usual dosage	0.6–1.4 μM (Rathkopf et al, 2010)	0.15 μM	Rasmussen et al (2015)
Romi	Romidepsin, FK228	Istodax	Peripheral T‐cell lymphoma or cutaneous T‐cell lymphoma	14 mg/m²	0.112 μM (Celgene (2014) Istodax prescribing information)	0.0175 μM	Sogaard et al (2015)